Completed PHASE4 INTERVENTIONAL 2-arm NCT00595504

Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia

Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia

Sponsor: Massachusetts General Hospital

Conditions Schizoaffective Disorder Schizophrenia Schizophreniform Disorders

Updated 7 times since 2017 Last updated: Aug 14, 2012 Started: Jan 31, 2008 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Schizoaffective Disorder and Schizophrenia, this trial is completed. The trial is conducted by Massachusetts General Hospital and has accumulated 7 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital
Takeda

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States